SLEEP APNEA
impacting your life?

See if the MARIPOSA Clinical Study is right for you.
Investigational oral medication. No masks or hoses.

The MARIPOSA Study for Obstructive
Sleep Apnea (OSA) - Now Enrolling

Obstructive Sleep Apnea (OSA) is a common and serious sleep disorder in which breathing is repeatedly interrupted during sleep. OSA occurs when the airway collapses as you breathe in. This can cause breathing to be paused from several seconds to over a minute.

While many people use continuous positive airway pressure (CPAP) machines to manage their OSA, these systems can be cumbersome and awkward for some.

Right now, doctors at select centers throughout the US are conducting a new research study that may be able to help. The study is called MARIPOSA and is for an investigational oral medication for OSA taken daily at bedtime.

The MARIPOSA Study lasts about 10 weeks and involves up to 7 visits to your local study center. If you qualify and choose to join the study, you will receive all study-related care and study medication at no cost, and will also be compensated for your time and travel to attend study visits.

Why Participate?

If you’re living with obstructive sleep apnea (OSA) and have not had lasting success with CPAP machines or other treatments, you may qualify for the MARIPOSA Clinical Study. The study is for an investigational oral medication for OSA taken daily at bedtime. If you qualify and choose to join the MARIPOSA Study, you will receive:

  • Evaluations of your OSA condition from a local physician specialist
  • Study-related care and study medication at no cost (health insurance is not required)
  • Compensation for your time and travel to attend study visits (approximately 7 visits over a 10-week period)
  • The opportunity to help advance OSA research and treatment options to potentially benefit others living with OSA

See If You Qualify

To see if you might qualify for the MARIPOSA Clinical Study, and to connect with a local study center to learn more, please take the questionnaire below.